SI-BONE Q2 2023 Earnings Report

SI-BONE EPS Results

• Actual EPS: -$0.30
• Consensus EPS: -$0.41
• Beat/Miss: Beat by +$0.11
• One Year Ago EPS: N/A

SI-BONE Revenue Results

• Actual Revenue: $33.31 million
• Expected Revenue: $32.24 million
• Beat/Miss: Beat by +$1.07 million
• YoY Revenue Growth: N/A

SI-BONE Announcement Details

• Quarter: Q2 2023
• Date: 8/7/2023
• Time: N/A

SI-BONE (NASDAQ:SIBN), a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.